key: cord-0017628-jiw1nywn authors: Spiegel, Rory S.; Radecki, Ryan P. title: Stop the MABness: June 2021 Annals of Emergency Medicine Journal Club date: 2021-05-22 journal: Ann Emerg Med DOI: 10.1016/j.annemergmed.2021.04.036 sha: 002f3864b58f048cb861c0ac1a5f2b5577e48b7d doc_id: 17628 cord_uid: jiw1nywn nan Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632-644. In patients with early, mild to moderate coronavirus disease 2019 (COVID-19), do neutralizing antibody treatments reduce symptom severity and subsequent hospital admissions? Design: Phase II/III, randomized, double-blind, placebo-controlled Setting: 139 outpatient health care facilities Population: 577 adult, non-hospitalized patients positive for SARS-CoV-2 and presenting with one or more mild or moderate symptoms of COVID-19 Intervention: Intravenous infusion of bamlanivimab, bamlanivimab and etesevimab, or placebo; five differing treatment and dose combinations were included. Primary and Secondary Outcomes: The primary outcome was change from baseline in the SARS-CoV-2 viral load at day 11 (AE4 days). Secondary outcomes included measures of symptom resolution at days 7, 11, 15, and 22, and proportion of patients with a COVID-19-related hospitalization. Sponsors: Eli Lilly and Company ClinicalTrials.gov Identifier: NCT04427501 How Did the Authors Interpret the Results? Of the 577 patients randomized, 101 received 700 mg of bamlanivimab, 107 received 2800 mg bamlanivimab, 101 patients received 7000 mg of bamlanivimab, 112 patients received bamlanivimab and etesevimab combination, and 156 patients received placebo. The authors report no significant difference in log change in viral load at 11 days between the placebo group and any of the 3 bamlanivimab monotherapy groups. In the combination therapy group, the authors report a statistically significant -0.57 (95% confidence interval [CI] -1.00 to -0.14, P ¼ .01) difference in the change in log viral load when compared to placebo. Differences in secondary outcomes were heterogenous among treatment arms and limited by small numbers of serious outcomes. The authors conclude among nonhospitalized patients with early, mild to moderate COVID-19 illness, combination treatment with bamlanivimab and etesevimab, compared with placebo, was associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11. These surrogate endpoints can neither confirm nor exclude clinical benefit from neutralizing antibodies. Further studies examining neutralizing antibody efficacy, powered to examine clinical outcomes, should be performed before these therapies are considered standard treatment for patients with COVID-19. 1. The authors describe this as a phase II/III trial. Describe the difference between the two types of trials. Which description is more appropriate for this trial's design? When developing new therapeutics in medicine, researchers often progress through various stages of investigation. Phase I trials are performed in early stages of therapeutic development. In this stage, therapies are tested on small cohorts of healthy volunteers. The purpose of phase I is confirming safety of the novel therapeutics prior to larger trials. Phase II trials test therapeutics on larger groups of patients. While larger than phase I trials, phase II trials typically still enroll relatively small samples. The goal of phase II trials is to refine dose-response relationships. The investigators often utilize multiple groups receiving differing doses of the therapeutic as well as placebo. Often, surrogate outcomes may be used, as they are typically easier to measure than more clinically relevant endpoints. Due to the small sample size, multiple treatment groups, and large number of datapoints measured, the risk of type 1 error in phase II trials is high. Positive results from phase II trials should be validated using a larger phase III trial design. Phase III trials are much larger and typically examine the therapeutic in question compared to placebo. These trials focus on clinically important outcomes in favor of surrogate outcomes used in the phase II trials. Gottlieb et al enrolled a total of 577 patients, randomizing them to four groups of active therapeutics and a single placebo. Three groups looked at different doses of bamlanivimab, and one examined bamlanivimab in combination with etesevimab. The authors powered the trial to detect a difference in viral load at 11 days, a surrogate for clinical improvement in COVID-19. In a preliminary report previously published in the NEJM, Chen et al 1 describe the study as a phase II trial (1) . Later in the full publication, it is described as a phase II/III trial. When one examines the current protocol available online at clinicaltrials.gov (NCT04427501), it appears a phase III portion of this trial is still ongoing. This trial intends to enroll a larger sample size comparing a single dose of bamlanivimab, bamlanivimab in combination with etesevimab, and placebo. While the current publication does present a number of clinical endpoints, given the multiple groups, small sample size, and focus on a surrogate outcome, this publication appears to be closer to a phase II design than phase III. 2. How might a phase III trial be designed to further clarify these outcomes? The authors found no statistically significant change in viral load nor COVID-19-related hospitalizations between any bamlanivamb monotherapy and placebo. They do, however, report a difference in the viral load at 11 days between the combination therapy group and placebo (-4.37 in the combination therapy group vs -3.80 in the placebo group, a difference of -0.57, 95% CI -1.00 to -0.14, P ¼ .01). They also report a difference in the number of patients with COVID-19-related hospitalizations or emergency department visits (ARR of -4.9%; 95% CI -8.9% to -0.8%; P ¼ .049). These results specifically call into question the utility of bamlanivamb monotherapy for treating early COVID-19. Further phase III trials should consider the hypothesis etesevimab is the active agent affecting surrogate and clinical outcomes. Assuming the etesevimab dose needs no further clarification, a well-designed phase III trial would include an etesevimab monotherapy arm, a combination arm, and placebo. Given the rarity of adverse clinical outcomes, overall, the required sample size to reliably demonstrate a precise effect size will be large. Furthermore, with the rise of variant mutations in circulating SARS-CoV-2, a confirmatory trial ought to additionally be powered to ensure clinically important differences across a variety of SARS-CoV-2 substrates. These considerations dramatically decrease the likelihood that reliable evidence for antibody therapeutics may be generated in a fashion informing contemporary practice. Section Editors: Tyler W. Barrett MD, MSCI; Ryan P. Radecki, MD, MS; Rory J. Spiegel, MD SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 Author affiliations: From Medstar Washington Hospital, Washington, DC (Spiegel); and Christchurch Hospital, Christchurch, NZ (Radecki).All authors attest to meeting the four ICMJE.org authorship criteria: (1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (2) Drafting the work or revising it critically for important intellectual content; AND (3) Final approval of the version to be published; AND (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.